CN103889423B - 奈妥匹坦和帕洛诺司琼的治疗性组合 - Google Patents

奈妥匹坦和帕洛诺司琼的治疗性组合 Download PDF

Info

Publication number
CN103889423B
CN103889423B CN201280051509.8A CN201280051509A CN103889423B CN 103889423 B CN103889423 B CN 103889423B CN 201280051509 A CN201280051509 A CN 201280051509A CN 103889423 B CN103889423 B CN 103889423B
Authority
CN
China
Prior art keywords
ibs
netupitant
purposes described
palonosetron
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280051509.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103889423A (zh
Inventor
克劳迪奥·彼得拉
S·坎托雷吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heersen Health Care Co Ltd
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Priority to CN201610834008.7A priority Critical patent/CN106974912A/zh
Priority to CN201510670710.XA priority patent/CN105412110B/zh
Publication of CN103889423A publication Critical patent/CN103889423A/zh
Application granted granted Critical
Publication of CN103889423B publication Critical patent/CN103889423B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280051509.8A 2011-10-18 2012-10-10 奈妥匹坦和帕洛诺司琼的治疗性组合 Active CN103889423B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201610834008.7A CN106974912A (zh) 2011-10-18 2012-10-10 奈妥匹坦和帕洛诺司琼的治疗性组合
CN201510670710.XA CN105412110B (zh) 2011-10-18 2012-10-10 奈妥匹坦和帕洛诺司琼的治疗性组合

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548514P 2011-10-18 2011-10-18
US61/548,514 2011-10-18
PCT/IB2012/002013 WO2013057554A2 (en) 2011-10-18 2012-10-10 Therapeutic combinations of netupitant and palonosetron

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201610834008.7A Division CN106974912A (zh) 2011-10-18 2012-10-10 奈妥匹坦和帕洛诺司琼的治疗性组合
CN201510670710.XA Division CN105412110B (zh) 2011-10-18 2012-10-10 奈妥匹坦和帕洛诺司琼的治疗性组合

Publications (2)

Publication Number Publication Date
CN103889423A CN103889423A (zh) 2014-06-25
CN103889423B true CN103889423B (zh) 2016-10-19

Family

ID=47178220

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201280051509.8A Active CN103889423B (zh) 2011-10-18 2012-10-10 奈妥匹坦和帕洛诺司琼的治疗性组合
CN201510670710.XA Active CN105412110B (zh) 2011-10-18 2012-10-10 奈妥匹坦和帕洛诺司琼的治疗性组合
CN201610834008.7A Pending CN106974912A (zh) 2011-10-18 2012-10-10 奈妥匹坦和帕洛诺司琼的治疗性组合

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510670710.XA Active CN105412110B (zh) 2011-10-18 2012-10-10 奈妥匹坦和帕洛诺司琼的治疗性组合
CN201610834008.7A Pending CN106974912A (zh) 2011-10-18 2012-10-10 奈妥匹坦和帕洛诺司琼的治疗性组合

Country Status (11)

Country Link
US (1) US9358228B2 (enExample)
EP (2) EP2744497B1 (enExample)
JP (1) JP2014530249A (enExample)
CN (3) CN103889423B (enExample)
DK (1) DK2744497T3 (enExample)
ES (1) ES2579616T3 (enExample)
HK (1) HK1198121A1 (enExample)
HU (1) HUE030811T2 (enExample)
PL (1) PL2744497T3 (enExample)
PT (1) PT2744497T (enExample)
WO (1) WO2013057554A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
TW202428273A (zh) 2023-01-03 2024-07-16 瑞士商赫爾辛保健公司 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011061622A1 (en) * 2009-11-18 2011-05-26 Helsinn Healthcare S.A. Compositions for treating centrally mediated nausea and vomiting

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0430190T3 (da) 1989-11-28 1995-08-21 Syntex Inc Hidtil ukendte tricykliske forbindelser
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
ATE434437T1 (de) * 1999-02-18 2009-07-15 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
ATE400556T1 (de) 2000-07-14 2008-07-15 Hoffmann La Roche N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
AU1608502A (en) 2000-12-14 2002-06-24 Hoffmann La Roche Self emulsifying lipid matrix (selm)
WO2004062623A2 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
SG154443A1 (en) 2004-07-01 2009-08-28 Schering Corp Piperidine derivatives as nk1 antagonists
AU2007247851A1 (en) * 2006-05-03 2007-11-15 Relevare Aust. Pty Ltd Methods and composition for treatment of inflammatory pain
ES2325339T3 (es) 2006-10-24 2009-09-01 Helsinn Healthcare S.A. Capsulas blandas que comprenden hidrocloruro de palonosetron que tienen una estabilidad y una biodisponibilidad mejoradas.
US20100316678A1 (en) 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011061622A1 (en) * 2009-11-18 2011-05-26 Helsinn Healthcare S.A. Compositions for treating centrally mediated nausea and vomiting

Also Published As

Publication number Publication date
CN106974912A (zh) 2017-07-25
CN105412110B (zh) 2018-05-25
EP2759298B1 (en) 2018-01-17
US20140256737A1 (en) 2014-09-11
JP2014530249A (ja) 2014-11-17
EP2744497A2 (en) 2014-06-25
DK2744497T3 (en) 2016-08-01
US9358228B2 (en) 2016-06-07
PL2744497T3 (pl) 2016-10-31
HK1194977A1 (zh) 2014-10-31
ES2579616T3 (es) 2016-08-12
EP2744497B1 (en) 2016-04-06
CN105412110A (zh) 2016-03-23
WO2013057554A2 (en) 2013-04-25
HK1198121A1 (en) 2015-03-13
EP2759298A1 (en) 2014-07-30
PT2744497T (pt) 2016-07-18
CN103889423A (zh) 2014-06-25
HUE030811T2 (hu) 2017-05-29
WO2013057554A3 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
TW201249425A (en) Cannabinoids for use in the treatment of neuropathic pain
RU2015103719A (ru) Пищевое волокно для применения при лечении побочного эффекта питания или лекарственного средства в отношении желудочно-кишечного тракта
WO2023227881A1 (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
CN103889423B (zh) 奈妥匹坦和帕洛诺司琼的治疗性组合
JP4746714B2 (ja) 線維筋痛症治療用医薬組成物
KR102374820B1 (ko) 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물
AU2019222781A1 (en) Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using Menthol, Linalool and/or Icilin
CN114788821A (zh) 一种药物组合物及其用途
HK1194977B (en) Therapeutic combinations of netupitant and palonosetron
JP4427329B2 (ja) 慢性疼痛の治療のための２−インダニルアミノ誘導体
CN118593461B (zh) 一种组合物、药物及其制备、检测、定位方法和用途
CN101411700B (zh) 5,7,4'-三羟基二氢黄酮或其衍生物用于止痛的用途
JP2014530249A5 (enExample)
Zouhri et al. Covid-19 with neuropathic pain symptom: A case-report
WO2020004463A1 (ja) 糖尿病性末梢神経障害の予防又は治療用組成物
HK1141436A1 (en) Axomadol for treating pain from arthritis
HK1193050A1 (zh) 用於治疗早泄的药物组合物以及用於治疗早泄的方法
HK1193050B (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
HK1141436B (en) Axomadol for treating pain from arthritis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Lugano Switzerland - bazzero

Patentee after: Heersen health care Co Ltd

Address before: Lugano Switzerland - bazzero

Patentee before: Helsinn Healthcare SA

CP01 Change in the name or title of a patent holder